OncoLens Secures $2.5M in Pre-Series A Funding


OncoLens, an Atlanta, GA-based provider of tumor board and cancer treatment planning software solutions, raised $2.5m in Pre-Series A funding.

The round was led by BIP Capital, with participation from Atlanta Technology Angels, and the Robbins Fund.

The company intends to use the funds to expand the capabilities of its solutions and grow its sales and marketing resources.

Led by Anju Mathew, co-founder and CEO, OncoLens develops technologies that improve cancer treatment planning, simplify tumor board management, facilitate survivorship care planning, and automate accreditation and quality reporting through an intelligent workflow engine that streamlines business processes and enables more informed clinical decision-making.

The company utilizes proprietary algorithms to decrease the workload around multidisciplinary case discussions by bringing together clinical, radiological, and pathological data required for collaboration. It automatically matches the patient with relevant clinical trials and potential targeted therapies while also providing quality improvement considerations for the care team.

The company currently serves several large integrated delivery networks (IDNs) and hospitals across the country.



Join the discussion